



Sponsorers syn på framtidens studier






Focused on R&D in three main therapy areas and across key platforms



Main therapy areas



Opportunity-led



Oncology



Cardiovascular
and metabolic
diseases



Respiratory



Autoimmunity,
neuroscience and
infection

Healthcare sector is best placed to benefit from the merging of physical, digital and biological systems, but it is among the least well prepared¹



1. Power to the patient: How mobile technology is transforming healthcare. The Economist Intelligence Unit Report 2015



Innovative medicines are needed more than ever

Source: WHO



8 million
lives claimed by
cancer every year



17 million
deaths from
cardiovascular disease
every year



347 million
people worldwide
have diabetes



235 million
people suffer from
asthma



Oncology

For more than 40 years, we have developed cancer drugs.

Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as cause of death.

Main therapy areas

- > Breast
- > Ovaries
- > Lungs
- > Hematologic

Specific orientations

- > Tumour drivers and resistance
- > DNA damage response (DDR)
- > Antibody conjugates
- > Immuno-oncology (IO)



Cardiovascular and Metabolic Diseases

Because we know that cardiovascular diseases are a well-known consequence of diabetes and chronic kidney disease, we take an integrated patient-centric approach. We seek to reduce cardiovascular morbidity and mortality, and organ damage by addressing multiple cardiovascular risk factors.

Cardiovascular and Metabolic Diseases

Focus on medicines for:

- > Thrombosis
- > Atherosclerosis
- > Dyslipidaemia
- > Hypertension
- > Heart failure
- > Diabetes
- > Chronic kidney disease (CKD)



Respiratory diseases

Our goal is to establish a leading position in asthma and COPD treatment, by delivering a range of differentiated inhaled therapies, novel combinations and devices, and biologics.

Respiratory

Working to transform disease management and patient outcomes in:

- > Asthma
- > COPD

Our research will potentially result in the first treatment of:

- > Idiopathic pulmonary fibrosis (IPF)

The future of Clinical Drug Development

Increased participation through reduced burden
(both patients and investigators)

Reduce cost and time while quality is non-negotiable

Technology and access will enable and force transformation



Digital 4.0 (digitalization, mobilization & patient power) will be disruptive and lead into a world of integrated/unified solutions

